Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Eoganachton Aug 08, 2021 2:21pm
393 Views
Post# 33669686

Exactly How Does TLD1433 Kill Cancer Cells?

Exactly How Does TLD1433 Kill Cancer Cells?Dr. McFarland intends to spend the next 3 years finding out, financed by an NSF award of $440,000. 

"...insight regarding the potential photobiological mechanism(s) of TLD1433 and related PSs could lead to the development of Ru(II) photodrugs with even better properties than TLD1433."

Restricted Research - Award List, Note/Discussion Page

Restricted Research - Award List, Note/Discussion Page
 
Fiscal Year: 2021
 
1330  The University of Texas at Arlington  (85626)
 
Principal Investigator: Sherri McFarland
 
Total Amount of Contract, Award, or Gift (Annual before 2011): $ 440,000
 
Exceeds $250,000 (Is it flagged?): Yes
 
Start and End Dates: 8/1/21 - 7/31/24
 
Restricted Research: New/Blank/Unresolved/Undetermined
 
Academic Discipline: College of Science
 
Department, Center, School, or Institute: Department of Chemistry and Biochemistry
 
Title of Contract, Award, or Gift: The Excited State Behavior of Ru(II) Photodrugs
 
Name of Granting or Contracting Agency/Entity: National Science Foundation (NSF)
CFDA Link: NSF
47.049
 
Program Title: Division of Chemistry: Disciplinary Research Programs (CHE-DRP)
CFDA Linked: Mathematical and Physical Sciences
 
Note:
 
The project will examine the excited state behavior of our TLD1433 and related Ru(II) photodrugs. We propose a new mechanism that may account for the very high photocytotoxicity that certain oligothiophene-containing Ru(II) photodrugs show toward cancer cells, both in normoxia and in hypoxia. The project also aims to develop the photophysical model(s) for these photosensitizers (PSs) in complex biological environments. More broadly, this work will generate new knowledge about the relationships between molecular structure, redox chemistry and photophysics, and potentially novel photocytotoxic mechanisms. This insight regarding the potential photobiological mechanism(s) of TLD1433 and related PSs could lead to the development of Ru(II) photodrugs with even better properties than TLD1433. Obj 1: We will synthesize and characterize oligothiophene-appended Ru(II) PSs, [Ru(LL)2(IP-nT)]2+, that differ in the number of thiophene rings (nT), the types of substituents on the thiophene rings, and the coligands (LL). The modifications are designed to vary redox potentials and triplet state characteristics and to alter the covalent and noncovalent associations typical of oligothiophenes. Obj 2: Electrochemical techniques will be used to test the hypothesis that the Ru(II) PSs can participate in biological photoredox catalysis, where biomolecules can be oxidized (or reduced) by a catalytic PS* with or without oxygen. The purpose is to show that photoredox catalysis is possible using simple biological substrates. (SAM Category: 1.1.1)

<< Previous
Bullboard Posts
Next >>